Use of dietary and herbal supplements and communication with hematologists regarding such use among patients with CLL: a national survey

Use of dietary and herbal supplements (DHS) is common among patients with chronic lymphocytic leukemia (CLL), but data in the era of targeted therapies are limited. We conducted a national prospective survey of Hebrew-speaking adults with CLL in Israel (2025), assessing DHS prevalence, patterns of use, sources of recommendation, reporting to hematologists, and patient expectations. Multivariate logistic regression identified factors associated with DHS use. Among 267 respondents, 49% reported current or past DHS use. Use was independently associated with female gender and residence in Central Israel. Most DHS were used for general or 'immune' strengthening, with high perceived effectiveness. Hematologists were the main advisors for 42% of DHS use, and 65% of patients disclosed DHS use to their physician. DHS use is common among patients with CLL and involves relatively high patient-hematologist communication, underscoring the need for evidence-based integrative counseling.

Authors

Institutions

Publication Details

Journal
Leukemia & lymphoma/Leukemia and lymphoma
Published
2026-02-11
DOI
https://doi.org/10.1080/10428194.2026.2628207
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Use of dietary and herbal supplements and communication with hematologists regarding such use among patients with CLL: a national survey

Tamar Tadmor, Samuel Pérez Attías, Lea Koren, Giora Sharf et al.
Leukemia & lymphoma/Leukemia and lymphoma
Chronic Lymphocytic Leukemia Research
article

Use of dietary and herbal supplements and communication with hematologists regarding such use among patients with CLL: a national survey

Tamar Tadmor, Samuel Pérez Attías, Lea Koren, Giora Sharf, Elad Schiff, Ilana Levy Yurkovski
article en

Abstract

Use of dietary and herbal supplements (DHS) is common among patients with chronic lymphocytic leukemia (CLL), but data in the era of targeted therapies are limited. We conducted a national prospective survey of Hebrew-speaking adults with CLL in Israel (2025), assessing DHS prevalence, patterns of use, sources of recommendation, reporting to hematologists, and patient expectations. Multivariate logistic regression identified factors associated with DHS use. Among 267 respondents, 49% reported current or past DHS use. Use was independently associated with female gender and residence in Central Israel. Most DHS were used for general or 'immune' strengthening, with high perceived effectiveness. Hematologists were the main advisors for 42% of DHS use, and 65% of patients disclosed DHS use to their physician. DHS use is common among patients with CLL and involves relatively high patient-hematologist communication, underscoring the need for evidence-based integrative counseling.

Leukemia & lymphoma/Leukemia and lymphoma
Bnai Zion Medical Center (IL), Leukemia and Lymphoma Society (US)
Gender equality
Openalex Percentile: Top 59%
Chronic Lymphocytic Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.